Bibliographie

1- Comité Français de Lutte contre l'hypertension Artérielle (CFLHTA). Enquête FLAHS 2010 (French League Against Hypertension Survey [FLAHS]). Les traitements par les antihypertenseurs en France en 2010 ?

2- HAS. Bon usage du médicament. Quel usage pour l’aliskiren (Rasilez®) dans le traitement antihypertenseur ? Septembre 2009.

3- Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 2009; 27:2121-2158.

4- The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010;362:1477-90.

5- NGCC. National Clinical Guideline Centre. Hypertension. The Clinical Management of primary hypertension in adults. Clinical guideline. Féb 2011. Draft for consultation.

6- Godet-Mardirossian H, Girerd X, Vernay M, Chamontin M, Katia Castetbon K, de Peretti C. Patterns of hypertension management in France (ENNS 2006–2007). Eur J Cardiovasc Prev Rehabil. 2011 Mar 30. [Epub ahead of print]

7- Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57(5):590-600.

8- Myers MG, Godwin M, Dawes M, Kiss A et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011;342:d286; doi:10.1136/bmj.d286

9- HAS. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle. Actualisation 2005. Recommandations. Juillet 2005.

10- The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010;362:1575-85.